Expression and bioinformatics analysis of miRNA in ISO-induced rat cardiac hypertrophy

doi:10.12047/j.cjap.5835.2019.104

Abstract

Abstract: Objective: To investigate the expression changes of miRNAs (miR199a-5P, miR206, miR133a-3P, miR499-5P) in rat model of cardiac hypertrophy induced by isoproterenol (ISO), and to explore the main signal pathways and molecular mechanisms which related to that with the way of bioinformatics. Methods: Sixteen SD male rats were randomly divided into two groups: control group and ISO model group. The rats in model group were treated with ISO (1 mg/kg) to induce cardiac hypertrophy, the rats in control group were treated with the same amount of saline, and all were injected subcutaneously at the back. After 10 days of continuous administration, interventricular septal thickness at diastole (IVSd), left ventricular posterior wall thickness at diastole (LVPWd) , left ventricular end-diastolic diameter(LVDd), and systolic function (EF%) were measured by echocardiography. Heart weight (HW) and rat body weight (BW) were weighed, and heart/body weight ratio (HW/BW) was calculated. Myocardial tissues were stained with HE, and myocardial cell surface area was measured by Image J analysis software; RT-qPCR was used to detect the expressions of 4 miRNAs in rat myocardial tissues. Targetscan, miRDB and miRwalk databases were used to predict the possible target genes of four kinds of miRNAs in rats, and FunRich software was used to analyze and predict the signal pathways related to the target genes. Results: Compared with the control group, the IVSd and LVPWd in the model group were thickened, the LV was increased, and the EF% was decreased significantly. The HW and HW/BW were increased. The myocardial cell volume in the model group was increased significantly, the arrangement was disordered, and the cell surface area was increased; the expressions of miR199a-5P and miR206 in the model group were up-regulated by RT-qPCR (P＜0.05); the expressions of miR133a-3P and miR499-5P were down-regulated (P＜0.05). Predicted by bioinformatics application, related signal pathways which target genes of 4 miRNAs maybe involved in cardiac hypertrophy mainly are: VEGF/VEGFR signal pathway, ErbB receptor signal pathway and other signal pathways. Conclusion: ISO-induced cardiac hypertrophy leads to changes in miRNA expression, and bioinformatics predicts related target genes of four miRNAs involved in cardiac hypertrophy and their major signaling pathways. These studies will provide new ideas for the regulation of cardiac hypertrophy and its prevention and treatment measures.

Key words: isoproterenol, miRNAs, cardiac hypertrophy, bioinformatics, rat

WU Xue-cui, ZHAO Yun, LI Cong, XIONG Hai-rong, ZHENG Zhi-wei, ZHOU Jun, LIU Rong, GONG Wei, LIU Chao-qi. Expression and bioinformatics analysis of miRNA in ISO-induced rat cardiac hypertrophy[J]. CJAP, 2019, 35(5): 476-480.

References

[1] Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association[J]. Circulation, 2018, 137(12): e67－e492.
[2] Bartel DP. MicroRNAs: Target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215-233.
[3] Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy[J]. Circ Res, 2007, 100(3): 416-424.
[4] Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy[J]? Am J Pathol, 2007, 170(6): 1831-1840.
[5] Zhang R, Dong DL, Yang BF. Basic research and application of microRNA--a novel target for regulating cardiac arrhythmias[J]. Acta Pharm Sinica, 2011, 46(1): 6-11.
[6] Condorelli G, Latronico M V G, Ii G W D. microRNAs in heart disease: putative novel therapeutic targets[J]? Eur Heart J, 2016, 31(6): 649-658.
[7] 程杰坤, 孙小慧, 高莉萍, 等. 法舒地尔对异丙肾上腺素诱导大鼠心肌肥厚的干预作用及其机制[J]. 中国应用生理学杂志, 2016, 32(5): 414-418.
[8] 王羽, 刘明洁, 付瑶, 等. 苏格木勒-3汤对异丙肾上腺素诱导的大鼠心肌肥厚Caspase3/9表达的影响[J]. 中国应用生理学杂志, 2017, 33(5): 390-392.
[9] 徐峰, 王景全, 白小涓, 等. 高频超声显像评价慢性压力负荷大鼠心肌结构和功能的动态变化[J]. 中华医学杂志(英文版), 2002, 115(4): 487-490.
[10]Dong DL, Yang BF. Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure[J]. Acta Pharm Sinica B, 2011, 1(1): 1-7.
[11]Wang J, Yang X. The function of miRNA in cardiac hypertrophy[J]. Cell Mol Life Sci, 2012, 69(21): 3561-3570.
[12]Gao J, Li YH, Wang TM, et al. Analyzing gene expression profiles with preliminary validations in cardiac hypertrophy induced by pressureoverload[J]. Can J Physiol Pharmacol, 2018, 96(8): 701-709.
[13]Zhang H, Li S, Zhou Q, et al. Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy through downregulation of MiR-199a-5p[J]. Cell Physiol Biochem, 2016, 38(5): 1743-1751.
[14]Rane S, He M, Sayed D, et al. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p[J]. Cell Signal, 2010, 22(7): 1054-1062.
[15]Yang Y, Re D p D, Nakano N, et al. miR-206 mediates YAp-induced cardiac hypertrophy and survival[J]. Circ Res, 2015, 117(10): 891-904.
[16]Shieh J T C , Huang Y, Gilmore J, et al. Elevated miR-499 levels blunt the cardiac stress response[J]. PLoS ONE, 2011, 6.
[17]吴扬, 郭媛媛, 张元媛, 等. H2S对大鼠心肌肥大与miRNA-133a和Ca2+/CaN/NFATc4信号通路的影响[J]. 中国应用生理学杂志, 2018, 34(1): 29-34.
[18]Shen J, Xie Y, Liu ZJ, et al. Increased myocardial stiffness activates cardiac microvascular endothelial cell via VEGF paracrine signaling in cardiac hypertrophy[J]. J Mol Cell Cardiol, 2018, 122: 140-151.
[19]Xu XH, Xu J, Xue L, et al. VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation[J]. J Cardiothorac Surg, 2011, 6(1): 54-62.
[20]Wang T, Li R, Lin C, et al. Copper suppression of vascular endothelial growth factor receptor-2 is involved in the regression of cardiomyocyte hypertrophy[J]. Exp Biol Med, 2014, 239(8): 948-953.
[21]Zou Y, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice [J]. J Cardiovasc Pharmacol, 2012, 59(3): 268-280.
[22]Li Z, Song Y, Liu L, et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation[J]. Cell Death Differ, 2017, 24(7): 1205-1213.
[23]Yan W, Guo L R, Zhang Q, et al. Chronic blockade of class I PI3-kinase attenuates Ang II-induced cardiac hypertrophy and autophagic alteration[J]. Eur Revr Med Pharmaco, 2015, 19(5): 772-783.
[24]Ferdous A, Battiprolu PK, Ni YG, et al. FoxO, autophagy, and cardiac remodeling[J]. J Cardiovasc Trans Res, 2010, 3(4): 355-364.
[25]Rifki O F, Hill J A . Cardiac autophagy: good with the bad[J]. J Cardiovasc Pharmacol, 2012, 60(3): 248-252.
[26]Lucas E, Vila-Bedmar R, Arcones AC, et al. Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels[J]. Cardiovascular Diabetology, 2016, 15(1): 155-168.
[27]Kolwicz SC, Tian R .Glucose metabolism and cardiac hypertrophy[J]. Cardiovascular Research, 2011, 90(2): 194-201.
[28]Zhang C, Wang F, Zhang Y, et al. Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress[J]. J Cell Mol Med, 2016, 20(1): 116-127.